Radiobiological and clinical bases for total body irradiation in the leukemias and lymphomas

doi:10.1016/S1053-4296(05)80028-1

Seminars in Radiation Oncology

Volume 5, Issue 4, October 1995, Pages 301-315

https://doi.org/10.1016/S1053-4296(05)80028-1 Get rights and content

In spite of the recent introduction of conditioning regimens consisting of chemotherapy alone, therapeutic total body irradiation (TBI) remains a powerful antileukemic and immunosuppressive tool in preparative regimens for bone marrow transplantation. However, the question of the “best” TBI schedule has not been answered. Available radiobiological and clinical data show that (1) the role of fractionation (or dose rate) on leukemia cell killing may vary with the leukemia type. Acute myeloid leukemia cells have been found to be insensitive or only slightly sensitive to fractionation, whereas chronic myeloid leukemia cells appear to be sensitive. Data are still controversial for acute lymphocytic leukemia and the non-Hodgkin's lymphomas; (2) the immunosuppressive effect of TBI is very fractionation sensitive; and (3) most normal tissues at risk are also highly sensitive to fractionation and dose rate. These data permit some cautious adaptations of the TBI schemes to the type of leukemia, use of T-cell-depleted donor marrow, and potential normal tissue toxicity. However, we still lack data concerning the precise intrinsic and fractionation radiosensitivity of the leukemia/lymphoma of a given patient. Recent improvements in leukemia-cell cultures allowing the generation of dose survival curves and the study of in vitro radiation-induced apoptosis (mainly for lymphomas) may soon provide radiation oncologists with the data to allow further refinement and individualization of TBI schedules.

References (187)

PetersLJ
Discussion: The radiobiological bases of TBI
Int J Radiat Oncol Biol Phys
(1980)
BarendsenGW
Dose fractionation, dose rate and isoeffect relationships for normal tissue responses
Int J Radiat Oncol Biol Phys
(1982)
O'DonoghueJA
Fractionated versus low-dose rate total body irradiation. Radiobiological considerations in the selection of regimes
Radiother Oncol
(1986)
ShankB
Techniques of magna field irradiation
Int J Radiat Oncol Biol Phys
(1983)
QuastU
Total body irradiation. Review of treatment techniques in Europe
Radiother Oncol
(1987)
KeaneTJ et al.
TBI schedules prior to bone marrow transplantation: Requirements for comparison
Radiother Oncol
(1989)
GaleRP et al.
Response to Vriesendorp et al.
Int J Radiat Oncol Biol Phys
(1991)
ChamplinR
Preparative regimens for autologous bone marrow transplantation
Blood
(1993)
ShankB
Can total body irradiation be supplanted by busulfan in cytoreductive regimens for bone marrow transplantation
Int J Radiat Oncol Biol Phys
(1994)
ShankB
Can total body irradiation be supplanted by busulfan in cytoreductive regimens for bone marrow transplantation
Int J Radiat Oncol Biol Phys
(1994)
CliftRA et al.
Marrow transplantation for chronic myeloid leukemia: A randomized study comparing cyclophosphamide and total body irradiation with busulfan and cyclophosphamide
Blood
(1994)

DarringtonDL et al.

Incidence and characterization of secondary myelodysplatic syndrome and acute myelogenous leukemia following high-dose chemotherapy and autologous stem-cell transplantation for lymphoid malignancies

J Clin Oncol

(1994)

StoneRM et al.

Myelodysplatic syndrome as a late complication following autologous bone marrow transplantation for non-Hodgkin's lymphoma

J Clin Oncol

(1994)

HorningSJ et al.

Fractionated total body irradiation, etoposide and cyclophosphamide plus autografting in Hodgkin's disease and non-Hodgkin's lymphoma

J Clin Oncol

(1994)

GaleRP et al.

What does total body irradiation do in bone marrow transplant for leukemia?

Int J Radiat Oncol Biol Phys

(1991)

WeichselbaumRR et al.

In vitro radiosensitivity of human leukemia cell lines

Radiology

(1981)

RheeJG et al.

Effect of fractionation and rate of radiation dose on human leukemic cells. HL 60

Radiat Res

(1985)

FitzgeraldTJ et al.

Effects of x-irradiation dose rate on the clonogenic survival of experimental animal hematopoietic tumor cell lines: Evidence for heterogeneity

Int J Radiat Oncol Biol Phys

(1986)

LehnertS et al.

Radiation response of hematopoietic cell lines of human origin

Int J Radiat Biol

(1986)

FitzgeraldTJ et al.

Radiosensitivity of cloned permanent murine bone marrow stromal cell lines; non uniform effect of low dose rate

Exp Hematol

(1988)

UckunFM et al.

Intrinsic radiation resistance of primary clonogenic blasts from children with newly diagnosed B-cell precursor acute lymphoblastic leukemia

J Clin Invest

(1993)

SantucciMA et al.

Expression of p210 BCR/ABL increases hematoprogenitor cell radiosensitivity

Int J Radiat Oncol Biol Phys

(1993)

DutreixJ et al.

Biological problems of total body irradiation

J Eur Radiother

(1982)

KimlerBF et al.

Radiation response of human normal and leukemic hemopoietic cells assayed by in vitro colony formation

Int J Radiat Oncol Biol Phys

(1985)

HagenbeekA et al.

Comparison of different total body irradiation regimes combined with bone marrow transplantation in a rat model for human myelocytic leukemia

Int J Radiat Biol

(1979)

UckunFM et al.

Radiobiological characteristics of normal and leukemic bone marrow progenitor cells

OzsahinM et al.

Total body irradiation before bone marrow transplantation; results of two randomized instantaneous dose rates in 157 patients

Cancer

(1992)

SocieG et al.

Influence of the fractionation of total body irradiation on complications and relapse rate for chronic myelogenous leukemia

Int J Radiat Oncol Biol Phys

(1991)

GoldmanJM et al.

Bone marrow transplantation for chronic myelogenous leukemia in chronic phase. Increased risk for relapse associated with T-Cell depletion

Ann Intern Med

(1988)

HaleG et al.

Campath: 1 for prevention of graft versus host disease and graft rejection. Summary of results from multi-centre study

Bone Marrow Transplant

(1988)

VernantJP et al.

Allogeneic bone marrow transplantation in 184 adults with acute lymphoid leukemia in first complete remission

HendryJH et al.

The response of hematopoietic colony forming units to single and split doses of gamma rays or D-T neutrons

Int J Radiat Biol

(1971)

ImaiY et al.

In vivo radiosensitivity and recovery pattern of the hematopoietic precursor cells and stem cells in mouse bone marrow

Exp Hematol

(1987)

BairdMC et al.

The radiosensitivity of human hematopoietic progenitor cells

Int J Radiat Biol

(1989)

GlasgowGP et al.

Dose rate effects on the survival of normal hematopoietic stem cells of BALB/C mice

Int J Radiat Oncol Biol Phys

(1983)

EvansRG et al.

Modification of radiation-induced damage to bone marrow stem cells by dose rate, dose fractionation and prior exposure to cytoxan as jucged by the survival of CFU-S: Application to bone marrow transplantation (BMT)

Int J Radiat Oncol Biol Phys

(1988)

HendryTH

A new derivation, from split course data, of the complete survival curve for clonogenic normal cells in vivo

Radiat Res

(1979)

GirinskyT et al.

Similar effects on murine haemopoietic compartment of low dose rate single dose and high dose rate fractionated total body irradiation. Preliminary results after a unique dose of 750 cGy

Br J Radiol

(1990)

StewartM et al.

Long-term engraftment of normal and post-5-fluorouracil murine marrow into normal non myeloablated mice

Blood

(1993)

HarrisonDE

Competitive repopulation in unirradiated normal recipients

Blood

(1993)

HalperinEC et al.

The influence of dose and dose rate of total lymphoid irradiation in the rat cardiac allograft model

Radiother Oncol

(1987)

FerrebeeJW et al.

Factors affecting the survival of transplanted tissues

Am J Med Sci

(1958)

PetersLJ et al.

Radiobiological considerations in the use of total body irradiation for bonemarrow transplantation

Radiology

(1979)

DaleRG

The application of the linear-quadratic dose effect equation to fractionated and protracted radiotherapy

Br J Radiol

(1985)

DaleRG

The application of the linear quadratic model to fractionated radiotherapy when there is incomplete normal tissue recovery between fractions, and possible implications for treatments involving multiple fractions per day

Br J Radiol

(1986)

LiversageWE

A general formula for equating protracted and acute regimes of radiation

Br J Radiol

(1969)

O'DonoghueJA et al.

The implications of in vitro survival curves for the optimal scheduling of total body irradiation with bone marrow rescue in the treatment of leukemia

Br J Radiol

(1987)

SteelGG et al.

Dose rate effects and the repair of radiation damage

Radiother Oncol

(1986)

ShankB

Radiotherapeutic principles of bone marrow transplantation

ThomasED

Total body irradiation regimes for marrow grafting

Int J Radiat Oncol Biol Phys

(1990)

AppelbaumFR et al.

Is there a better way to deliver total body irradiation?

Bone Marrow Transplant

(1992)

Cited by (35)

Radiobiologic Principles and the Role of Radiotherapy in Hematopoietic Cell Transplant and Chimeric Antigen Receptor T-Cell Therapy
2023, Manual of Hematopoietic Cell Transplantation and Cellular Therapies
Radiotherapy is an established therapeutic option for hematologic malignancies in a variety of contexts. In this chapter, we will review the mechanism of action of external beam radiotherapy and radiobiologic principles that guide dose and fractionation regimens commonly used today. We will discuss the role of radiotherapy before transplant, from myeloablative to reduced-intensity conditioning total-body-irradiation regimens, as well as total marrow and total lymphoid irradiation. We will also discuss the use of radiotherapy in unique clinical scenarios including extramedullary disease involving the central nervous system and skin. We will summarize the data supporting the use of radiotherapy in the setting of chimeric antigen receptor T-cell therapy, both in the bridging and salvage setting, and highlight considerations for radiotherapy dose, target, and timing.
Volumetric Modulated Arc Therapy Enabled Total Body Irradiation (VMAT-TBI): Six-year Clinical Experience and Treatment Outcomes
2022, Transplantation and Cellular Therapy
Citation Excerpt :
Similar results were obtained in a recent VMAT-TBI study by Tas et al. [22] in which a higher instantaneous dose rate (ranged 50-600 MU/min, 0.24-0.36 Gy/min) was used and no grade 3+ lung toxicity occurred in any patient (n = 30). Many prior studies have shown that dose rate appears to have little effect on toxicities in fractionated TBI, especially with the reduced dose to the lungs [35–40]. We plan to systematically investigate higher dose rate in future patients with the goal of decreasing treatment time if safe to do so.
Total body irradiation is an important part of the conditioning regimens frequently used to prepare patients for allogeneic hematopoietic stem cell transplantation (SCT). Volumetric-modulated arc therapy enabled total body irradiation (VMAT-TBI), an alternative to conventional TBI (cTBI), is a novel radiotherapy treatment technique that has been implemented and investigated in our institution. The purpose of this study is to (1) report our six-year clinical experience in terms of treatment planning strategy and delivery time and (2) evaluate the clinical outcomes and toxicities in our cohort of patients treated with VMAT-TBI. This is a retrospective single center study. Forty-four patients at our institution received VMAT-TBI and chemotherapy conditioning followed by allogeneic SCT between 2014 and 2020. Thirty-two patients (73%) received standard-dose TBI (12-13.2 Gy in 6-8 fractions twice daily), whereas 12 (27%) received low-dose TBI (2-4 Gy in one fraction). Treatment planning, delivery, and treatment outcome data including overall survival (OS), relapse-free survival (RFS), and toxicities were analyzed. The developed VMAT-TBI planning strategy consistently generated plans satisfying our dose constraints, with planning target volume coverage >90%, mean lung dose ∼50% to 75% of prescription dose, and minimal hotspots in critical organs. Most of the treatment deliveries were <100 minutes (range 33-147, mean 72). The median follow-up was 26 months. At the last follow-up, 34 of 44 (77%) of patients were alive, with 1- and 2-year OS of 90% and 79% and RFS of 88% and 71%, respectively. The most common grade 3+ toxicities observed were mucositis (31 patients [71%]) and nephrotoxicity (6 patients [13%]), both of which were deemed multifactorial in cause. Four patients (9%) in standard-dose cohort developed grade 3+ pneumonitis, with 3 cases in the setting of documented respiratory infection and only 1 (2%) deemed likely related to radiation alone. VMAT-TBI provides a safe alternative to cTBI. The dose modulation capability of VMAT-TBI may lead to new treatment strategies, such as simultaneous boost and further critical organ sparing, for better malignant cell eradication, immune suppression, and lower toxicities.
Simplified low-dose-rate infant total body irradiation
2017, Practical Radiation Oncology
Citation Excerpt :
Total body irradiation (TBI) is an important component of conditioning regimens before hematopoietic stem cell transplantation. Radiobiologically, the rationale for low-dose-rate (LDR) TBI (5 to 10 cGy/minute) is that hematopoietic cells demonstrate little sublethal damage repair in comparison to nonhematologic tissue, allowing for improved therapeutic ratio.1 Ozashin et al conducted a randomized study of 157 patients undergoing stem cell transplantation to LDR or high-dose-rate TBI and found high dose rate was associated with increased development of cataracts.2,3
Low-dose-rate total body irradiation (LDR TBI) in infants possesses unique challenges because of the setup limitations imposed by anesthesia. We present an LDR TBI method with an anteroposterior/posteroanterior arrangement and dose rate < 10 cGy/minute for infants (thickness <14 cm) without the use of a beam attenuator.
The delivery used a 6 MV TrueBeam linear accelerator (Varian Medical Systems, Palo Alto, CA) with adjustable meterset rates below 100 MU/minute. A platform was constructed to support the patient 6 cm above the floor (~2 m from the source). A 40 × 40 cm² field at isocenter along with a 45° collimator rotation was used to achieve a maximum field width of approximately 113 cm at 2 m. The patient was positioned supine with head turned toward the patient’s right side for the anteroposterior beam and prone with the head continuing to turn towards the patient’s right side for the posteroanterior beam. A scattering plate with custom organ blocks was placed approximately 20 cm from the patient’s skin surface. Output, depth-dose, surface-dose, block transmission, and off-axis measurements were taken using solid water slabs, ion chambers, and film.
The TrueBeam provides several options for this treatment geometry to deliver LDR TBI at less than 10 cGy/min by lowering the linear accelerator meterset rate below 100 MU/minute. This allowed for a compromise between dose rate and treatment time to be selected by the radiation oncology team without the use of a beam attenuator, thus improving patient safety. Depth-dose and off-axis measurements confirmed a dose distribution within ±5% of the central-axis dose. A scattering plate distance of ~20 cm from the patient increases surface dose while allowing easy access to the patient during anesthesia.
The method described is useful to pediatric radiation oncologists seeking to deliver LDR TBI to an infant patient.
Total Body Irradiation
2015, Clinical Radiation Oncology
Total Body Irradiation
2012, Clinical Radiation Oncology: Third Edition
Total Body Irradiation
2011, Clinical Radiation Oncology, Third Edition

View all citing articles on Scopus

View full text